製薬の世界市場

製薬の世界市場は2030年までに35億米ドルに達する

2023年に18億米ドルと推定される製薬の世界市場は、2023年から2030年にかけてCAGR 9.8％で成長し、2030年には35億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである医薬品製薬は、CAGR 8.3％を記録し、分析期間終了時には21億米ドルに達すると予測されています。ヘルスケア製薬分野の成長率は、分析期間中CAGR 12.4%と推定されます。

米国市場は4億8,390万米ドルと推定、中国はCAGR 9.2％で成長予測

米国の製薬市場は、2023年に4億8,390万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに5億4,090万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは9.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.5%と8.3%と予測されています。欧州では、ドイツがCAGR約7.7%で成長すると予測されています。

世界の製薬市場- 主要動向と促進要因のまとめ

製薬市場が世界の医薬品業界の成長促進要因として注目される理由とは？

製薬市場は、ヘルスケアインフラの急速な拡大、慢性疾患の増加、新興国における医薬品の値ごろ感の高まりにより、世界の医薬品業界における成長の主要促進要因として脚光を浴びています。製薬」とは、医薬品の消費と販売が急成長している新興国の医薬品市場を指します。これらの国々には、中国、インド、ブラジル、ロシア、東南アジアなどの地域が含まれ、中流階級の人口の拡大、医療アクセスの改善、医療インフラへの投資の拡大を特徴としています。その結果、ジェネリック医薬品、一般用医薬品（OTC）、革新的な治療法を含む医薬品に対する需要が、これらの市場で大幅に増加しています。

製薬市場は、製薬企業にとってプレゼンスを拡大し、新たな収益源を開拓する大きな機会となるため、世界の製薬産業の成長を牽引する上で重要な役割を果たしています。欧米式ヘルスケアの導入が進んでいることに加え、医療保険制度や医療費の負担を改善するための政府の取り組みが、これらの地域の医薬品需要を押し上げています。さらに、ライフスタイルの変化、都市化、高齢化などを背景に、糖尿病、心血管疾患、がんなどの慢性疾患の罹患率が上昇していることも、慢性疾患治療薬と特殊治療薬の両方に対する旺盛な需要を生み出しています。世界の医薬品売上高に占める製薬市場の割合が高まっていることから、北米や欧州といった成熟市場の成長鈍化を補おうとする多国籍製薬企業にとって、戦略的な焦点となっています。

技術の進歩とヘルスケア改革は、製薬市場をどのように変えているのか？

技術の進歩とヘルスケア改革は、ヘルスケアデリバリーを改善し、ドラッグアクセシビリティを高め、革新的な治療法の採用を促進することで、製薬市場を変革しています。この分野における最も重要な進歩の一つは、遠隔医療、モバイルヘルスアプリケーション、電子カルテ（EHR）などのデジタルヘルス技術の利用拡大であり、遠隔地や十分なサービスを受けていない地域における医療アクセスと患者の転帰を改善しています。特に遠隔医療は、医療提供者が実際に訪問することなく患者に診察、診断、治療提案を提供できるため、製薬市場で人気を博しています。慢性疾患管理、服薬アドヒアランス、健康教育にモバイルヘルスアプリケーションを利用することで、患者のエンゲージメントをサポートし、予防医療の実践を促しています。

ヘルスケアにおけるデジタル技術の統合はまた、健康データの収集と分析を可能にし、より良い疾病管理とヘルスケア計画を支援しています。EHRや医療情報システムは、患者のデータ管理を合理化し、治療結果を改善し、医療ミスを減らすために利用されています。これらの技術は、ヘルスケアへのアクセス、資源の制約、ヘルスケアの質に関する課題の克服を支援し、医薬品セクター全体の成長を支えています。さらに、医療技術評価（HTA）の枠組みや薬剤経済学的評価の導入により、製薬市場の政府や医療費負担者は、新しい治療法や医療介入の採用に関して十分な情報に基づいた意思決定を行うことができるようになり、医療資源の効率的な利用が保証されています。

また、医療アクセスや医療費の負担の軽減を目的としたヘルスケア改革も、製薬市場の変革に重要な役割を果たしています。多くの製薬諸国は、国民皆保険制度（UHC）、国民健康保険制度、価格抑制策を実施し、必要不可欠な医薬品やヘルスケア・サービスをより多くの国民が利用できるようにしています。例えば、インド政府の「アユシュマン・バラート」健康保険制度や中国の国家償還医薬品リスト（NRDL）改革は、何百万人もの国民にとって医薬品の入手可能性と購入可能性を高めています。これらの改革は、ブランド医薬品とジェネリック医薬品の両方の需要を促進し、製薬企業にとって十分なサービスを受けていない人々に医薬品を届ける新たな機会を生み出しています。

さらに、政府がヘルスケア支出を削減するために費用対効果の高い治療法の使用を推進する中、バイオシミラーやジェネリック医薬品の採用が製薬市場で勢いを増しています。生物学的製剤の廉価版であるバイオシミラーは、がん、関節リウマチ、糖尿病などの治療において、高価な生物学的製剤に代わる治療薬として受け入れられつつあります。また、ジェネリック医薬品の使用は、現地での製造や迅速な規制当局の承認を支援する政策を通じて奨励されています。これらの施策は、薬価の引き下げと安価な治療薬の普及に貢献し、これらの地域の医薬品市場の成長を支えています。技術の進歩とヘルスケア改革が製薬市場の形を変え続ける中、世界な事業展開を目指す製薬企業にとっては、よりアクセスしやすく、効率的で魅力的な市場となっています。

製薬市場の成長において、政府のイニシアティブと現地製造はどのような役割を果たしていますか？

政府の取り組みと現地生産は、医薬品生産を支援し、輸入への依存を減らし、ヘルスケアの手頃な価格を高める環境を促進することによって、製薬市場の成長を促進する上で極めて重要な役割を果たしています。多くの製薬諸国は、国内の医薬品生産を促進し、外国直接投資（FDI）を奨励し、国内製薬企業と多国籍製薬企業の双方に有利なビジネス条件を整備することを目的とした政策やプログラムを実施しています。これらのイニシアチブは、医薬品生産の自給率を高め、必要不可欠な医薬品の安定供給を確保し、現地で製造されたジェネリック医薬品やバイオシミラーの使用を促進することを目的としています。

現地生産は、生産コストの削減、薬価の引き下げ、安価な医薬品へのアクセスの改善に役立つため、製薬市場において特に重要です。インドや中国といった国々は、世界のジェネリック医薬品と原薬の大部分を供給する、医薬品製造の世界の中心地としての地位を確立しています。強力な現地製造拠点の存在により、これらの国々は高品質な医薬品を市場競争力のある価格で製造することができ、必要不可欠な医薬品を国内外の市場でより入手しやすくしています。税制優遇措置、補助金、インフラ整備といった形での政府の支援は、これらの地域の医薬品製造部門をさらに強化し、市場の成長を促進しています。

地域の医薬品イノベーションと研究開発を促進することを目的とした政府の取り組みも、製薬市場の成長に影響を与えています。新製剤、新規ドラッグデリバリーシステム、バイオシミラーの開発を支援するプログラムは、現地の製薬企業が製品ポートフォリオを強化し、世界市場で競争する上で役立っています。例えば、中国の「Made in China 2025」構想やインドの「Pharma Vision 2020」は、国内の製薬業界のイノベーション能力を高め、世界の医薬品バリューチェーンへの貢献度を高めることに重点を置いています。製薬リサーチパーク、インキュベーションセンター、官民パートナーシップの設立は、産学官の連携を促進し、製薬市場特有の医療ニーズに対応する革新的な医薬品の開拓を支援しています。

さらに、医薬品の承認プロセスを合理化し、国際的な品質基準への準拠を確保することを目的とした規制改革が実施され、医薬品市場の成長を促す環境が整いつつあります。製薬市場の規制機関は、医薬品製造管理及び品質管理基準（GMP）などの国際的ガイドラインを採用し、規制の枠組みを世界スタンダードと調和させることで、より迅速な市場参入を促進し、現地で生産される医薬品の競争力を高めています。こうした改革は、多国籍製薬企業による現地製造施設の設立や現地パートナーとの協力を促し、製薬市場の成長をさらに後押ししています。

また、政府の政策によってヘルスケアの低価格化とアクセシビリティの向上が重視されていることも、製薬市場の医薬品需要を押し上げています。各国政府は、必要不可欠な医薬品が手ごろな価格で入手できるよう、価格統制、大量調達プログラム、償還政策を実施しています。こうした施策は、ジェネリック医薬品やバイオシミラーといった費用対効果の高い治療法の採用を後押しし、医薬品市場の成長を促進しています。政府の取り組みと現地生産能力が進化を続ける中、これらは製薬市場の将来を形成し、医薬品業界に新たな成長機会を生み出す上で重要な役割を果たしています。

世界の製薬市場の成長を促進する要因は？

世界の製薬市場の成長は、中間層人口の拡大、医療費の増加、慢性疾患の有病率の上昇、新興経済諸国におけるヘルスケアインフラ整備への注目の高まりなど、いくつかの要因によって牽引されています。主な成長要因の一つは、新興諸国における急速な経済発展と可処分所得の増加です。中流階級の人口が拡大するにつれて、ヘルスケアサービスや医薬品に支出する余裕のある個人が増え、処方薬と一般用医薬品の両方の需要増につながっています。中国、インド、ブラジル、ロシアなどの消費者の購買力が高まっていることが医薬品市場の拡大に寄与しており、収益源の多様化を目指す製薬企業にとってこれらの地域は魅力的な市場となっています。

製薬市場における医療支出の増加も、市場成長に寄与する重要な要因です。これらの地域の政府および民間セクターは、ヘルスケア・インフラに多額の投資を行い、医療保険の適用範囲を拡大し、医療サービスの利用しやすさと手ごろさを向上させる政策を実施しています。こうした投資によって医療提供の質が向上し、医薬品の利用が増加しています。病院、診療所、ヘルスケア施設の新設は、急性期治療薬から専門治療薬まで幅広い医薬品需要を生み出し、これらの地域の医薬品市場の成長を支えています。

糖尿病、高血圧、心血管障害、がんなどの慢性疾患の有病率の上昇が、製薬市場の成長をさらに後押ししています。都市化、高齢化、ライフスタイルの変化などの要因によって慢性疾患の罹患率が増加しているため、長期投薬や専門療法に対する強い需要が生まれています。慢性疾患の負担増は、政府やヘルスケアプロバイダーに疾病予防、早期診断、効果的な管理を優先させるよう促し、医薬品の消費増につながっています。生物学的製剤やバイオシミラーといった革新的な治療法の登場は、慢性疾患や複雑な疾患の治療を支え、市場の成長をさらに後押ししています。

さらに、製薬市場における医薬品製造能力の拡大が、世界の医薬品サプライチェーンの成長に寄与しています。インドや中国などの国々は、原薬やジェネリック医薬品の主要サプライヤーとしての地位を確立しており、国内外市場にコスト効率の高い医薬品を供給しています。強力な製造基盤の存在により、製薬諸国は拡大する医薬品需要に対応し、輸入依存度を減らし、世界の医薬品輸出のシェアを拡大することができます。医薬品製造クラスター、自由貿易区、輸出促進プログラムの発展は、世界の医薬品産業における製薬市場の競争力をさらに高めています。

さらに、製薬市場では、公衆衛生への関心が高まり、国民皆保険制度が実施されることで、医薬品市場拡大の新たな機会が生まれています。各国政府は、特に低所得層や農村部におけるヘルスケアへのアクセスや適用範囲を改善するための政策を実施しています。医療保険制度の拡大、償還リストに含まれる医薬品の増加、プライマリー・ヘルスケア・ネットワークの確立などが、幅広い医薬品需要を牽引しています。必要不可欠な医薬品やヘルスケアサービスへのアクセス拡大に注力することが、製薬地域の医薬品市場の成長を支えています。

さらに、COVID-19パンデミックの影響により、製薬市場のヘルスケア・インフラと医薬品生産への投資が加速しています。パンデミックは、強固なヘルスケアシステムと医薬品生産の自給自足の必要性を浮き彫りにしました。製薬市場の各国政府は、ヘルスケアシステムを強化し、必要不可欠な医薬品を確保するために、ヘルスケアインフラ、公衆衛生イニシアティブ、医薬品製造能力への投資を増やしています。各国がヘルスケアの強靭性を高め、国民の健康成果を改善しようとしているため、こうした投資が製薬市場の長期的な成長を促進すると予想されます。医療アクセスの拡大、革新的な治療法に対する需要の高まり、新興経済諸国における医薬品製造能力の現地開拓の重要性の高まりに支えられ、これらの要因が重なり合うことで、世界の製薬市場は力強い成長を遂げようとしています。

調査対象企業の例（注目の22社）

• Abbott Laboratories
• AbbVie, Inc.
• Alexion Pharmaceuticals, Inc.
• Allergan PLC
• Amgen, Inc.
• Aspen Pharmacare Holdings Ltd.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Bayer AG
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• CSL Behring
• Daiichi Sankyo Co., Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Endo International PLC
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Grifols SA
• H. Lundbeck A/S
• Hospira, Inc.
• Johnson & Johnson
• Kyowa Hakko Kirin Co., Ltd.
• Mallinckrodt Pharmaceuticals
• Mitsubishi Tanabe Pharma Corporation
• Mylan Pharmaceutical Pvt. Ltd.
• Novartis AG
• Novo Nordisk A/S
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi SA
• Shire PLC
• Stada Arzneimittel AG
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB SA

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Pharmerging Market to Reach US$3.5 Billion by 2030

The global market for Pharmerging estimated at US$1.8 Billion in the year 2023, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 9.8% over the analysis period 2023-2030. Pharmaceutical Pharmerging, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Healthcare Pharmerging segment is estimated at 12.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$483.9 Million While China is Forecast to Grow at 9.2% CAGR

The Pharmerging market in the U.S. is estimated at US$483.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$540.9 Million by the year 2030 trailing a CAGR of 9.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.5% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.7% CAGR.

Global Pharmerging Market - Key Trends & Drivers Summarized

Why Is the Pharmerging Market Gaining Prominence as a Key Driver of Growth in the Global Pharmaceutical Industry?

The pharmerging market is gaining prominence as a key driver of growth in the global pharmaceutical industry due to the rapid expansion of healthcare infrastructure, increasing prevalence of chronic diseases, and rising affordability of medicines in emerging economies. The term "pharmerging" refers to pharmaceutical markets in emerging countries that are experiencing rapid growth in pharmaceutical consumption and sales. These countries, which include regions such as China, India, Brazil, Russia, and Southeast Asia, are characterized by expanding middle-class populations, improving healthcare access, and growing investment in healthcare infrastructure. As a result, the demand for pharmaceuticals, including generic drugs, over-the-counter (OTC) medications, and innovative therapies, is increasing significantly in these markets.

Pharmerging markets are playing a critical role in driving the global pharmaceutical industry’s growth as they offer substantial opportunities for pharmaceutical companies to expand their presence and tap into new revenue streams. The increasing adoption of Western-style healthcare practices, coupled with government initiatives to improve healthcare coverage and affordability, is boosting the demand for medicines in these regions. Moreover, the rising incidence of chronic diseases such as diabetes, cardiovascular disorders, and cancer—driven by changing lifestyles, urbanization, and aging populations—is creating a strong demand for both chronic and specialty medications. The pharmerging markets’ growing share of global pharmaceutical sales is making them a strategic focus for multinational pharmaceutical companies seeking to offset slowing growth in mature markets such as North America and Europe.

How Are Technological Advancements and Healthcare Reforms Transforming the Pharmerging Market?

Technological advancements and healthcare reforms are transforming the pharmerging market by improving healthcare delivery, enhancing drug accessibility, and facilitating the adoption of innovative therapies. One of the most significant advancements in this space is the increased use of digital health technologies, such as telemedicine, mobile health applications, and electronic health records (EHRs), which are improving healthcare access and patient outcomes in remote and underserved areas. Telemedicine, in particular, has gained traction in pharmerging markets as it enables healthcare providers to offer consultations, diagnostics, and treatment recommendations to patients without the need for physical visits. The use of mobile health applications for chronic disease management, medication adherence, and health education is supporting patient engagement and encouraging the adoption of preventive healthcare practices.

The integration of digital technologies in healthcare is also enabling the collection and analysis of health data, supporting better disease management and healthcare planning. EHRs and health information systems are being used to streamline patient data management, improve treatment outcomes, and reduce medical errors. These technologies are helping pharmerging markets overcome challenges related to healthcare accessibility, resource constraints, and healthcare quality, supporting the overall growth of the pharmaceutical sector. Furthermore, the implementation of health technology assessment (HTA) frameworks and pharmacoeconomic evaluations is enabling governments and healthcare payers in pharmerging markets to make informed decisions regarding the adoption of new therapies and healthcare interventions, ensuring that healthcare resources are used efficiently.

Healthcare reforms aimed at expanding healthcare access and affordability are also playing a pivotal role in transforming the pharmerging market. Many pharmerging countries are implementing universal health coverage (UHC) schemes, national health insurance programs, and price control measures to ensure that essential medicines and healthcare services are accessible to a larger segment of the population. For example, the Indian government’s “Ayushman Bharat” health insurance scheme and China’s National Reimbursement Drug List (NRDL) reforms are increasing the availability and affordability of medications for millions of citizens. These reforms are driving demand for both branded and generic drugs, creating new opportunities for pharmaceutical companies to reach underserved populations.

Additionally, the adoption of biosimilars and generic drugs is gaining momentum in pharmerging markets as governments promote the use of cost-effective therapies to reduce healthcare expenditures. Biosimilars, which are lower-cost versions of biologic drugs, are being increasingly accepted as alternatives to expensive biologic therapies in treating conditions such as cancer, rheumatoid arthritis, and diabetes. The use of generics is also being encouraged through policies that support local manufacturing and faster regulatory approvals. These measures are helping to lower drug prices and increase the availability of affordable treatments, supporting the growth of the pharmaceutical market in these regions. As technological advancements and healthcare reforms continue to reshape the pharmerging market, they are making it more accessible, efficient, and attractive for pharmaceutical companies looking to expand their global footprint.

What Role Do Government Initiatives and Local Manufacturing Play in Driving the Growth of the Pharmerging Market?

Government initiatives and local manufacturing are playing a pivotal role in driving the growth of the pharmerging market by fostering an environment that supports pharmaceutical production, reduces dependency on imports, and enhances healthcare affordability. Many pharmerging countries are implementing policies and programs aimed at boosting domestic pharmaceutical production, encouraging foreign direct investment (FDI), and creating favorable business conditions for both local and multinational pharmaceutical companies. These initiatives are designed to develop self-sufficiency in drug production, ensure a stable supply of essential medicines, and promote the use of locally produced generics and biosimilars.

Local manufacturing is particularly significant in pharmerging markets as it helps reduce production costs, lower drug prices, and improve access to affordable medications. Countries such as India and China have established themselves as leading global hubs for pharmaceutical manufacturing, supplying a large portion of the world’s generic drugs and active pharmaceutical ingredients (APIs). The presence of a strong local manufacturing base enables these countries to produce high-quality pharmaceuticals at competitive prices, making essential medicines more accessible to domestic and international markets. Government support in the form of tax incentives, subsidies, and infrastructure development is further strengthening the pharmaceutical manufacturing sector in these regions, driving market growth.

Government initiatives aimed at promoting local pharmaceutical innovation and R&D are also influencing the growth of the pharmerging market. Programs that support the development of new drug formulations, novel drug delivery systems, and biosimilars are helping local pharmaceutical companies enhance their product portfolios and compete in the global market. For instance, China’s “Made in China 2025” initiative and India’s “Pharma Vision 2020” are focused on boosting the domestic pharmaceutical industry’s capacity for innovation and increasing its contribution to the global pharmaceutical value chain. The establishment of pharmaceutical research parks, incubation centers, and public-private partnerships is facilitating collaboration between academia, industry, and government, supporting the development of innovative drug products that address the specific healthcare needs of pharmerging markets.

Moreover, the implementation of regulatory reforms aimed at streamlining the drug approval process and ensuring compliance with international quality standards is creating a more conducive environment for pharmaceutical market growth. Regulatory bodies in pharmerging markets are adopting international guidelines such as Good Manufacturing Practices (GMP) and harmonizing their regulatory frameworks with global standards to facilitate faster market entry and increase the competitiveness of locally produced drugs. These reforms are encouraging multinational pharmaceutical companies to establish local manufacturing facilities and collaborate with local partners, further boosting the growth of the pharmerging market.

The emphasis on improving healthcare affordability and accessibility through government policies is also driving demand for pharmaceutical products in pharmerging markets. Governments are implementing pricing controls, bulk procurement programs, and reimbursement policies to ensure that essential medicines are available at affordable prices. These measures are supporting the adoption of cost-effective therapies such as generics and biosimilars, driving the growth of the pharmaceutical market. As government initiatives and local manufacturing capabilities continue to evolve, they are playing a crucial role in shaping the future of the pharmerging market and creating new growth opportunities for the pharmaceutical industry.

What Factors Are Driving the Growth of the Global Pharmerging Market?

The growth in the global pharmerging market is driven by several factors, including the expanding middle-class population, increasing healthcare expenditures, rising prevalence of chronic diseases, and the growing focus on healthcare infrastructure development in emerging economies. One of the primary growth drivers is the rapid economic development and rise in disposable incomes in pharmerging countries. As the middle-class population expands, more individuals can afford to spend on healthcare services and pharmaceutical products, leading to increased demand for both prescription and over-the-counter medications. The growing purchasing power of consumers in countries such as China, India, Brazil, and Russia is contributing to the expansion of the pharmaceutical market, making these regions attractive for pharmaceutical companies looking to diversify their revenue streams.

The increasing healthcare expenditures in pharmerging markets are another key factor contributing to market growth. Governments and private sectors in these regions are investing heavily in healthcare infrastructure, expanding healthcare coverage, and implementing policies to improve the availability and affordability of medical services. These investments are enhancing the quality of healthcare delivery and increasing the utilization of pharmaceutical products. The establishment of new hospitals, clinics, and healthcare facilities is creating demand for a wide range of medications, from acute care drugs to specialty therapies, supporting the growth of the pharmaceutical market in these regions.

The rising prevalence of chronic diseases such as diabetes, hypertension, cardiovascular disorders, and cancer is further driving the growth of the pharmerging market. The increasing incidence of chronic conditions, driven by factors such as urbanization, aging populations, and changes in lifestyle, is creating a strong demand for long-term medications and specialty therapies. The growing burden of chronic diseases is prompting governments and healthcare providers to prioritize disease prevention, early diagnosis, and effective management, leading to increased consumption of pharmaceuticals. The availability of innovative therapies, such as biologics and biosimilars, is supporting the treatment of chronic and complex diseases, further boosting market growth.

Moreover, the expanding pharmaceutical manufacturing capabilities in pharmerging markets are contributing to the growth of the global pharmaceutical supply chain. Countries such as India and China have established themselves as leading suppliers of APIs and generic drugs, providing cost-effective pharmaceutical products to both domestic and international markets. The presence of a strong manufacturing base is enabling pharmerging countries to meet the growing demand for pharmaceuticals, reduce dependency on imports, and increase their share of global pharmaceutical exports. The development of pharmaceutical manufacturing clusters, free trade zones, and export promotion programs is further enhancing the competitiveness of pharmerging markets in the global pharmaceutical industry.

Additionally, the increasing focus on public health and the implementation of universal health coverage schemes in pharmerging markets are creating new opportunities for pharmaceutical market expansion. Governments are implementing policies to improve healthcare access and coverage, particularly for low-income populations and rural communities. The expansion of health insurance schemes, the inclusion of more drugs in reimbursement lists, and the establishment of primary healthcare networks are driving demand for a wide range of pharmaceutical products. The focus on expanding access to essential medicines and healthcare services is supporting the growth of the pharmaceutical market in pharmerging regions.

Furthermore, the impact of the COVID-19 pandemic has accelerated investments in healthcare infrastructure and pharmaceutical production in pharmerging markets. The pandemic highlighted the need for robust healthcare systems and self-sufficiency in pharmaceutical production. Governments in pharmerging markets are increasing investments in healthcare infrastructure, public health initiatives, and pharmaceutical manufacturing capacity to strengthen their healthcare systems and ensure the availability of essential medicines. These investments are expected to drive long-term growth in the pharmerging market, as countries seek to enhance their healthcare resilience and improve health outcomes for their populations. As these factors converge, the global pharmerging market is poised for robust growth, supported by expanding healthcare access, rising demand for innovative therapies, and the increasing emphasis on developing local pharmaceutical manufacturing capabilities across various emerging economies.

Select Competitors (Total 22 Featured) -

• Abbott Laboratories
• AbbVie, Inc.
• Alexion Pharmaceuticals, Inc.
• Allergan PLC
• Amgen, Inc.
• Aspen Pharmacare Holdings Ltd.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Baxter International, Inc.
• Bayer AG
• Biogen, Inc.
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Celgene Corporation
• CSL Behring
• Daiichi Sankyo Co., Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Endo International PLC
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Grifols SA
• H. Lundbeck A/S
• Hospira, Inc.
• Johnson & Johnson
• Kyowa Hakko Kirin Co., Ltd.
• Mallinckrodt Pharmaceuticals
• Mitsubishi Tanabe Pharma Corporation
• Mylan Pharmaceutical Pvt. Ltd.
• Novartis AG
• Novo Nordisk A/S
• Otsuka Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi SA
• Shire PLC
• Stada Arzneimittel AG
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB SA

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Pharmerging - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Healthcare Expenditure and Access to Healthcare Propels Growth in Pharmerging Markets
  • Increasing Adoption of Generic and Low-Cost Pharmaceuticals Expands Addressable Market for Pharmerging Countries
  • Case Overview: Growth in Geriatric Population and Chronic Disease Incidence Bodes Well for Pharmerging Markets Expansion
  • Rising Focus on Enhancing Healthcare Infrastructure and Distribution Channels Drives Market Adoption
  • Increasing Use of Modern and Traditional Medicine Combinations Expands Market Scope
  • Technological Advancements in Cold Chain Logistics and Pharmaceutical Supply Chain Management Propel Market Growth
  • Focus on Complying with International Quality Standards and Regulations Strengthens Market Demand
  • Case Overview: Growth in Use of Digital Health and Telemedicine Solutions Expands Market Reach for Pharmerging Countries
  • Increasing Use of Pharmerging Solutions in Healthcare Startups and Innovative Ventures Expands Market Scope
  • Case Overview: Growth in Pharmaceutical Research and Clinical Trial Activities Expands Market Reach
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Pharmerging Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Pharmerging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World 7-Year Perspective for Pharmerging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 5: World 7-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Healthcare by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 7: World 7-Year Perspective for Healthcare by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 8: USA Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 9: USA 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• CANADA
  • TABLE 10: Canada Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 11: Canada 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• JAPAN
  • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 12: Japan Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 13: Japan 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• CHINA
  • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 14: China Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 15: China 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• EUROPE
  • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 16: Europe Recent Past, Current & Future Analysis for Pharmerging by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 17: Europe 7-Year Perspective for Pharmerging by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
  • TABLE 18: Europe Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 19: Europe 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• FRANCE
  • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 20: France Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 21: France 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• GERMANY
  • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 22: Germany Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 23: Germany 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• ITALY
  • TABLE 24: Italy Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 25: Italy 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• UNITED KINGDOM
  • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 26: UK Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: UK 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• REST OF EUROPE
  • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 29: Rest of Europe 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• ASIA-PACIFIC
  • Pharmerging Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 31: Asia-Pacific 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030
• REST OF WORLD
  • TABLE 32: Rest of World Recent Past, Current & Future Analysis for Pharmerging by Product - Pharmaceutical and Healthcare - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Rest of World 7-Year Perspective for Pharmerging by Product - Percentage Breakdown of Value Sales for Pharmaceutical and Healthcare for the Years 2024 & 2030

IV. COMPETITION